nach oben

The Patient - Patient-Centered Outcomes Research

Erschienen in:

01.12.2013 | Review Article

Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

verfasst von: Meenakshi Bewtra, F. Reed Johnson

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel disease (IBD), consisting of both Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the intestinal tract. As there is no cure for either CD or UC, patients with these conditions face numerous treatment decisions regarding their disease. The aim of this review is to evaluate literature regarding quantitative studies of patient preferences in therapy for IBD with a focus on the emerging technique of stated preference and its application in IBD. Numerous simple survey-based studies have been performed evaluating IBD patients’ preferences for medication frequency, mode of delivery, potential adverse events, etc., as well as variations in these preferences. These studies are limited, however, as they are purely descriptive in nature with limited quantitative information on the relative value of treatment alternatives. Time trade-off and standard-gamble studies have also been utilized to quantify patient utility for various treatment options or outcomes. However, these types of studies suffer from inaccurate assumptions regarding patient choice behavior. Stated preference is an emerging robust methodology increasingly utilized in health care that can determine the relative utility for a therapy option as well as its specific attributes (such as efficacy or adverse side effects). Stated preference techniques have begun to be applied in IBD and offer an innovative way of examining the numerous therapy options these patients and their providers face.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.PubMed

Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn’s disease. Gastroenterol Clin North Am. 2004;33:303–17, ix–x.

Hanauer S, Sninsky C, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124:204–11.

Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–85.PubMed

Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med. 1991;115:350–5.PubMed

Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188–97.PubMed

Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398–407.PubMed

Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137:1934–43.e1–3.

Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMed

10.

Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13.PubMed

11.

Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2006;51:1833–40.PubMed

12.

Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003;238:433–41; discussion 442–5.

13.

Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597–601.PubMed

14.

Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.PubMed

15.

Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol. 2001;96:1977–97.PubMed

16.

Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011;17:1415–22.PubMed

17.

Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–55.PubMed

18.

Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122:1808–14.PubMed

19.

Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599–613.PubMed

20.

Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–88.PubMed

21.

Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723–9.PubMed

22.

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMed

23.

Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(1827–1837):e2.PubMed

24.

McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(2):CD000297.

25.

Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342:1627–32.PubMed

26.

Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;(6):CD000545.

27.

Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD000067.

28.

Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.PubMed

29.

Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.PubMed

30.

Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.PubMed

31.

Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18.PubMed

32.

Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.PubMed

33.

Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212–21.PubMed

34.

Lichtenstein GR, Cohen R, Feagan BG, et al. Safety of infliximab and other Crohn’s disease therapies: Treat™ Registry data with 24,575 patient-years of follow-up. Am J Gastroenterol. 2008;103.

35.

Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428–35; quiz 1436.

36.

Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006;4:621–30.PubMed

37.

Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.PubMed

38.

Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1–16.PubMed

39.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:1017–24; quiz 976.

40.

Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.PubMed

41.

Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009;10:816–24.PubMed

42.

Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33.PubMed

43.

Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631–6.PubMed

44.

Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:598–605.PubMed

45.

Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.PubMed

46.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.PubMed

47.

Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–53.PubMed

48.

Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.PubMed

49.

Khan WA, Yu L, Eisenbrey AB, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients: report of two cases and review of literature. Am J Clin Pathol. 2001;116:41–50.PubMed

50.

Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–8.PubMed

51.

Moran G, Dillon J, Green J. Crohn’s disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? Inflamm Bowel Dis. 2009;15:1281–2.PubMed

52.

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.PubMed

53.

Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–13.PubMed

54.

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMed

55.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50.PubMed

56.

Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004;33:209–34, viii.

57.

Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.PubMed

58.

Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ. 2007;335:1033.PubMed

59.

Alves A, Panis Y, Mathieu P, et al. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 2005;140:278–83, discussion 284.

60.

Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48:70–3.PubMed

61.

Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–7.PubMed

62.

Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221–8.PubMed

63.

Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379–85.PubMed

64.

Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5:39.PubMed

65.

Bach SP, Mortensen NJ. Ileal pouch surgery for ulcerative colitis. World J Gastroenterol. 2007;13:3288–300.PubMed

66.

Sacristan JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak. 2013;13:6.PubMed

67.

Truog RD. Patients and doctors: evolution of a relationship. N Engl J Med. 2012;366:581–5.PubMed

68.

Laine C, Davidoff F. Patient-centered medicine: a professional evolution. JAMA. 1996;275:152–6.PubMed

69.

Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51:1087–110.PubMed

70.

Rademakers J, Delnoij D, Nijman J, de Boer D. Educational inequalities in patient-centred care: patients’ preferences and experiences. BMC Health Serv Res. 2012;12:261

71.

Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns. 2000;39:17–25.PubMed

72.

Mohamed AF, Hauber AB, Johnson FR, Coon CD. Patient preferences and linear scoring rules for patient-reported outcomes. Patient. 2010;3:217–27.PubMed

73.

Bala MV, Zarkin GA. Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ. 2000;9:177–80.PubMed

74.

Giesler RB, Ashton CM, Brody B, et al. Assessing the performance of utility techniques in the absence of a gold standard. Med Care. 1999;37:580–8.PubMed

75.

O’Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making. 1995;15:132–7.PubMed

76.

Lin MR, Yu WY, Wang SC. Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch Phys Med Rehabil. 2012;93:245–52.PubMed

77.

Bleichrodt H, Pinto J. The validity of QALYs under non-expected utility. Econ J. 2005;115:533–50.

78.

Brazier J, Rowen D, Yang Y, Tsuchiya A. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ. 2012;13:575–87.PubMed

79.

Hauber AB. Healthy-years equivalent: wounded but not yet dead. Expert Rev Pharmacoecon Outcomes Res. 2009;9:265–9.PubMed

80.

Johnson FR. Editorial: moving the QALY forward or just stuck in traffic? Value Health. 2009;12(Suppl 1):S38–9.PubMed

81.

Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health. 2009;12(Suppl 1):S10–5.PubMed

82.

Wong S, Walker JR, Carr R, et al. The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol. 2012;26:525–31.PubMed

83.

Conrad S, Huppe A, Raspe H. Preference of patients with inflammatory bowel disease regarding information and shared decision-making: results from a cross-sectional survey in Germany. Z Gastroenterol. 2012;50:364–72.PubMed

84.

Bernstein KI, Promislow S, Carr R, Rawsthorne P, Walker JR, Bernstein CN. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:590–8.PubMed

85.

Siegel C, Schwartz L, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Disease. 2010;16:1658–62.

86.

Baars J, Siegel C, van’t Spijker A, Markus T, Kuipers E, van der Woude C. Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis 2010;42:777–84.

87.

Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010;10:1

88.

Lewis JR, Konda V, Rubin DT. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009;13:495–503.PubMed

89.

Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther. 2009;29:1114–20.PubMed

90.

Knopf JM, Hornung RW, Slap GB, DeVellis RF, Britto MT. Views of treatment decision making from adolescents with chronic illnesses and their parents: a pilot study. Health Expect. 2008;11:343–54.PubMed

91.

Kennedy ED, To T, Steinhart AH, Detsky A, Llewellyn-Thomas HA, McLeod RS. Do patients consider postoperative maintenance therapy for Crohn’s disease worthwhile? Inflamm Bowel Dis. 2008;14:224–35.PubMed

92.

Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006;12:497–502.PubMed

93.

Rutter MD, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible costs and benefits of ulcerative colitis surveillance: a patient survey. Dis Colon Rectum. 2006;49:1177–83.PubMed

94.

Cheung WY, Dove J, Lervy B, Russell IT, Williams JG. Shared care in gastroenterology: GPs’ views of open access to out-patient follow-up for patients with inflammatory bowel disease. Fam Pract. 2002;19:53–6.PubMed

95.

Green TJ, Issenman RM, Jacobson K. Patients’ diets and preferences in a pediatric population with inflammatory bowel disease. Can J Gastroenterol. 1998;12:544–9.PubMed

96.

Probert CS, Mayberry JF. Inflammatory bowel disease: patients’ expectations in the 1990s. J R Soc Med. 1991;84:131–2.PubMed

97.

Johnson FR, Hauber AB, Osoba D, Hsu MA, Coombs J, Copley-Merriman C. Are chemotherapy patients’ HRQoL importance weights consistent with linear scoring rules? A stated-choice approach. Qual Life Res. 2006;15:285–98.PubMed

98.

Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1–6.PubMed

99.

Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135–42.PubMed

100.

McLeod RS, Churchill DN, Lock AM, Vanderburgh S, Cohen Z. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101:1307–13.PubMed

101.

Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn’s disease. Med Decis Mak. 2000;20:72–8.

102.

Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001;120:1640–56.PubMed

103.

Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50:586–97.PubMed

104.

Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794–9.PubMed

105.

Waljee AK, Morris AM, Waljee JF, Higgins PD. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1328–32.PubMed

106.

Brown LK, Waljee AK, Higgins PD, Waljee JF, Morris AM. Proximity to disease and perception of utility: physicians’ vs patients’ assessment of treatment options for ulcerative colitis. Dis Colon Rectum. 2011;54:1529–36.PubMed

107.

Leshno M. On using the standard gamble to determine utilities for uncertain health states. Med Decis Making. 2001;21:82–3.PubMed

108.

Deaton A, Muellbauer J. Economics and consumer behavior. Cambridge, UK: Cambridge University Press; 1980.

109.

Starmer C. Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk. J Econ Lit. 2000;38:332–82.

110.

Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Mak. 2011;31:469–80.

111.

Apter AJ, Paasche-Orlow MK, Remillard JT, et al. Numeracy and communication with patients: they are counting on us. J Gen Intern Med. 2008;23:2117–24.PubMed

112.

Fagerlin A, Ubel PA, Smith DM, Zikmund-Fisher BJ. Making numbers matter: present and future research in risk communication. Am J Health Behav. 2007;31(Suppl 1):S47–56.PubMed

113.

Elting LS, Martin CG, Cantor SB, Rubenstein EB. Influence of data display formats on physician investigators’ decisions to stop clinical trials: prospective trial with repeated measures. BMJ. 1999;318:1527–31.PubMed

114.

Reyna VF, Brainerd CJ. Numeracy, ratio bias, and denominator neglect in judgments of risk and probability. Learn Individ Differ. 2008;18:89–107.

115.

Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13:608–18.PubMed

116.

Garcia-Retamero R, Galesic M. Communicating treatment risk reduction to people with low numeracy skills: a cross-cultural comparison. Am J Public Health. 2009;99:2196–202.PubMed

117.

Burkell J. What are the chances? Evaluating risk and benefit information in consumer health materials. J Med Libr Assoc. 2004;92:200–8.PubMed

118.

Brase GL. Which statistical formats facilitate what decisions? The perception and influence of different statistical information formats. J Behav Decis Mak. 2002;15:381–401.

119.

Yamagishi K. When a 12.86% mortality is more dangerous then 24.14%: implications for risk communication. Appl Cogn Psychol. 1997;11:495–506.

120.

Galesic M, Gigerenzer G, Straubinger N. Natural frequencies help older adults and people with low numeracy to evaluate medical screening tests. Med Decis Mak. 2009;29:368–71.

121.

Cavanaugh K, Wallston KA, Gebretsadik T, et al. Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care. 2009;32:2149–55.PubMed

122.

Fagerlin A, Wang C, Ubel PA. Reducing the influence of anecdotal reasoning on people’s health care decisions: is a picture worth a thousand statistics? Med Decis Mak. 2005;25:398–405.

123.

Hawley ST, Zikmund-Fisher B, Ubel P, Jancovic A, Lucas T, Fagerlin A. The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Educ Couns. 2008;73:448–55.PubMed

124.

Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Mak. 2007;27:672–80.

125.

Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson AN. Assessing values for health: numeracy matters. Med Decis Mak. 2001;21:382–90.

126.

Zikmund-Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations. Med Decis Mak. 2007;27:663–71.

127.

Johnson FR, Banzhaf MR, Desvousges WH. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ. 2000;9:295–317.PubMed

128.

Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002;37:1681–705.PubMed

129.

Ryan M, Hughes J. Using conjoint analysis to assess women’s preferences for miscarriage management. Health Econ. 1997;6:261–73.PubMed

130.

Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S. Patients’ benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother. 2010;44:479–88.PubMed

131.

Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554–62.PubMed

132.

Johnson FR, Ozdemir S, Hauber B, Kauf TL. Women’s willingness to accept perceived risks for vasomotor symptom relief. J Womens Health (Larchmt). 2007;16:1028–40.

133.

Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-risk individuals’ willingness to pay for diabetes risk-reduction programs. Diabetes Care. 2006;29:1351–6.PubMed

134.

Lichtenstein G, Waters H, Kelly J, et al. Assessing drug treatment preferences of patients with Crohn’s disease, a conjoint analysis. Patient. 2010;3:113–23.

135.

Johnson FR, Ozdemir S, Mansfield C, et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769–79.PubMed

136.

Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29:121–36.PubMed

137.

Johnson FR, Hauber B, Ozdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manag Care Pharm. 2010;16:616–28.PubMed

138.

Hodgkins P, Swinburn P, Solomon D, Yen L, Dewilde S, Lloyd A. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient. 2012;5:33–44.PubMed

139.

Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13.PubMed

140.

Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3–13.

Titel: Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data
verfasst von: Meenakshi Bewtra
F. Reed Johnson
Publikationsdatum: 01.12.2013
Verlag: Springer International Publishing
Erschienen in: The Patient - Patient-Centered Outcomes Research / Ausgabe 4/2013
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI: https://doi.org/10.1007/s40271-013-0031-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Development of a Questionnaire to Assess the Impact of Chronic Low Back Pain for Use in Regulated Clinical Trials

Night-Time Symptoms and Their Impact on Sleep in Patients with Gastroesophageal Reflux Disease Who Have a Partial Response to Proton Pump Inhibitors: A Qualitative Patient Interview Study

Carer Preferences in Economic Evaluation and Healthcare Decision Making

Trust and Safe Spaces: Mental Health Consumers’ and Carers’ Relationships with Community Pharmacy Staff

Acknowledgement to Referees

Alternatives to Seclusion and Restraint in Psychiatry and in Long-Term Care Facilities for the Elderly: Perspectives of Service Users and Family Members